Umbilical cord plasma concentrate has beneficial effects on DNA methylation GrimAge and human clinical biomarkers
Plasma transfusions are standard treatments to replace missing proteins in people with rare genetic diseases. Prior studies have demonstrated that heterochronic parabiosis has beneficial effects on several tissues of old animals receiving young blood. Human clinical trials are currently underway to...
Saved in:
| Published in | Aging cell Vol. 21; no. 10; pp. e13696 - n/a |
|---|---|
| Main Authors | , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
John Wiley & Sons, Inc
01.10.2022
John Wiley and Sons Inc |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Plasma transfusions are standard treatments to replace missing proteins in people with rare genetic diseases. Prior studies have demonstrated that heterochronic parabiosis has beneficial effects on several tissues of old animals receiving young blood. Human clinical trials are currently underway to investigate whether the infusion of plasma or plasma‐derived factors from young donors can be used to mitigate human age‐related conditions. Here, we use data from a safety study (n = 18, mean age 74) to investigate whether human umbilical cord plasma concentrate (hereinafter Plasma Concentrate) injected weekly (1 ml intramuscular) into elderly human subjects over a 10‐week period affects different biomarkers, including epigenetic age measures, standard clinical biomarkers of organ dysfunction, mitochondrial DNA copy number (mtDNA‐CN), and leukocyte telomere length. This study shows that treatment with plasma concentrate is safe. More than 20 clinical biomarkers were significantly and beneficially altered following the treatments. For example, creatinine was significantly decreased (p = 0.0039), while estimated glomerular filtration rate (eGFR) was increased (p = 0.0044), indicating the treatment may improve biomarkers of kidney function. Three of four immunoglobulin biomarkers decreased, while telomere length and mtDNA‐CN were not significantly affected by the treatment. The treatment reduced DNA methylation‐based GrimAge by an average of 0.82 years (p = 0.0093), suggests a reduction in morbidity and mortality risk. By contrast, no significant results could be observed for epigenetic clocks that estimate chronological age. Our results support the view that plasma concentrate contains youth‐promoting factors.
We conducted a safety study (n = 18, mean age 74) by injecting human umbilical cord plasma concentrate (hereinafter Plasma Concentrate) weekly (1 ml intramuscular) into elderly human subjects over a 10‐week period. Our results indicate that treatment with plasma concentrate is safe. In addition, the treatment reduced DNA methylation‐based GrimAge, suggesting a reduction in morbidity and mortality risk. Taken together, our results support the view that plasma concentrate contains youth‐promoting factors. |
|---|---|
| AbstractList | Plasma transfusions are standard treatments to replace missing proteins in people with rare genetic diseases. Prior studies have demonstrated that heterochronic parabiosis has beneficial effects on several tissues of old animals receiving young blood. Human clinical trials are currently underway to investigate whether the infusion of plasma or plasma‐derived factors from young donors can be used to mitigate human age‐related conditions. Here, we use data from a safety study (
n
= 18, mean age 74) to investigate whether human umbilical cord plasma concentrate (hereinafter Plasma Concentrate) injected weekly (1 ml intramuscular) into elderly human subjects over a 10‐week period affects different biomarkers, including epigenetic age measures, standard clinical biomarkers of organ dysfunction, mitochondrial DNA copy number (mtDNA‐CN), and leukocyte telomere length. This study shows that treatment with plasma concentrate is safe. More than 20 clinical biomarkers were significantly and beneficially altered following the treatments. For example, creatinine was significantly decreased (
p
= 0.0039), while estimated glomerular filtration rate (eGFR) was increased (
p
= 0.0044), indicating the treatment may improve biomarkers of kidney function. Three of four immunoglobulin biomarkers decreased, while telomere length and mtDNA‐CN were not significantly affected by the treatment. The treatment reduced DNA methylation‐based GrimAge by an average of 0.82 years (
p
= 0.0093), suggests a reduction in morbidity and mortality risk. By contrast, no significant results could be observed for epigenetic clocks that estimate chronological age. Our results support the view that plasma concentrate contains youth‐promoting factors. Plasma transfusions are standard treatments to replace missing proteins in people with rare genetic diseases. Prior studies have demonstrated that heterochronic parabiosis has beneficial effects on several tissues of old animals receiving young blood. Human clinical trials are currently underway to investigate whether the infusion of plasma or plasma‐derived factors from young donors can be used to mitigate human age‐related conditions. Here, we use data from a safety study (n = 18, mean age 74) to investigate whether human umbilical cord plasma concentrate (hereinafter Plasma Concentrate) injected weekly (1 ml intramuscular) into elderly human subjects over a 10‐week period affects different biomarkers, including epigenetic age measures, standard clinical biomarkers of organ dysfunction, mitochondrial DNA copy number (mtDNA‐CN), and leukocyte telomere length. This study shows that treatment with plasma concentrate is safe. More than 20 clinical biomarkers were significantly and beneficially altered following the treatments. For example, creatinine was significantly decreased (p = 0.0039), while estimated glomerular filtration rate (eGFR) was increased (p = 0.0044), indicating the treatment may improve biomarkers of kidney function. Three of four immunoglobulin biomarkers decreased, while telomere length and mtDNA‐CN were not significantly affected by the treatment. The treatment reduced DNA methylation‐based GrimAge by an average of 0.82 years (p = 0.0093), suggests a reduction in morbidity and mortality risk. By contrast, no significant results could be observed for epigenetic clocks that estimate chronological age. Our results support the view that plasma concentrate contains youth‐promoting factors. We conducted a safety study (n = 18, mean age 74) by injecting human umbilical cord plasma concentrate (hereinafter Plasma Concentrate) weekly (1 ml intramuscular) into elderly human subjects over a 10‐week period. Our results indicate that treatment with plasma concentrate is safe. In addition, the treatment reduced DNA methylation‐based GrimAge, suggesting a reduction in morbidity and mortality risk. Taken together, our results support the view that plasma concentrate contains youth‐promoting factors. Plasma transfusions are standard treatments to replace missing proteins in people with rare genetic diseases. Prior studies have demonstrated that heterochronic parabiosis has beneficial effects on several tissues of old animals receiving young blood. Human clinical trials are currently underway to investigate whether the infusion of plasma or plasma‐derived factors from young donors can be used to mitigate human age‐related conditions. Here, we use data from a safety study ( n = 18, mean age 74) to investigate whether human umbilical cord plasma concentrate (hereinafter Plasma Concentrate) injected weekly (1 ml intramuscular) into elderly human subjects over a 10‐week period affects different biomarkers, including epigenetic age measures, standard clinical biomarkers of organ dysfunction, mitochondrial DNA copy number (mtDNA‐CN), and leukocyte telomere length. This study shows that treatment with plasma concentrate is safe. More than 20 clinical biomarkers were significantly and beneficially altered following the treatments. For example, creatinine was significantly decreased ( p = 0.0039), while estimated glomerular filtration rate (eGFR) was increased ( p = 0.0044), indicating the treatment may improve biomarkers of kidney function. Three of four immunoglobulin biomarkers decreased, while telomere length and mtDNA‐CN were not significantly affected by the treatment. The treatment reduced DNA methylation‐based GrimAge by an average of 0.82 years ( p = 0.0093), suggests a reduction in morbidity and mortality risk. By contrast, no significant results could be observed for epigenetic clocks that estimate chronological age. Our results support the view that plasma concentrate contains youth‐promoting factors. We conducted a safety study ( n = 18, mean age 74) by injecting human umbilical cord plasma concentrate (hereinafter Plasma Concentrate) weekly (1 ml intramuscular) into elderly human subjects over a 10‐week period. Our results indicate that treatment with plasma concentrate is safe. In addition, the treatment reduced DNA methylation‐based GrimAge, suggesting a reduction in morbidity and mortality risk. Taken together, our results support the view that plasma concentrate contains youth‐promoting factors. Plasma transfusions are standard treatments to replace missing proteins in people with rare genetic diseases. Prior studies have demonstrated that heterochronic parabiosis has beneficial effects on several tissues of old animals receiving young blood. Human clinical trials are currently underway to investigate whether the infusion of plasma or plasma-derived factors from young donors can be used to mitigate human age-related conditions. Here, we use data from a safety study (n = 18, mean age 74) to investigate whether human umbilical cord plasma concentrate (hereinafter Plasma Concentrate) injected weekly (1 ml intramuscular) into elderly human subjects over a 10-week period affects different biomarkers, including epigenetic age measures, standard clinical biomarkers of organ dysfunction, mitochondrial DNA copy number (mtDNA-CN), and leukocyte telomere length. This study shows that treatment with plasma concentrate is safe. More than 20 clinical biomarkers were significantly and beneficially altered following the treatments. For example, creatinine was significantly decreased (p = 0.0039), while estimated glomerular filtration rate (eGFR) was increased (p = 0.0044), indicating the treatment may improve biomarkers of kidney function. Three of four immunoglobulin biomarkers decreased, while telomere length and mtDNA-CN were not significantly affected by the treatment. The treatment reduced DNA methylation-based GrimAge by an average of 0.82 years (p = 0.0093), suggests a reduction in morbidity and mortality risk. By contrast, no significant results could be observed for epigenetic clocks that estimate chronological age. Our results support the view that plasma concentrate contains youth-promoting factors. Plasma transfusions are standard treatments to replace missing proteins in people with rare genetic diseases. Prior studies have demonstrated that heterochronic parabiosis has beneficial effects on several tissues of old animals receiving young blood. Human clinical trials are currently underway to investigate whether the infusion of plasma or plasma‐derived factors from young donors can be used to mitigate human age‐related conditions. Here, we use data from a safety study (n = 18, mean age 74) to investigate whether human umbilical cord plasma concentrate (hereinafter Plasma Concentrate) injected weekly (1 ml intramuscular) into elderly human subjects over a 10‐week period affects different biomarkers, including epigenetic age measures, standard clinical biomarkers of organ dysfunction, mitochondrial DNA copy number (mtDNA‐CN), and leukocyte telomere length. This study shows that treatment with plasma concentrate is safe. More than 20 clinical biomarkers were significantly and beneficially altered following the treatments. For example, creatinine was significantly decreased (p = 0.0039), while estimated glomerular filtration rate (eGFR) was increased (p = 0.0044), indicating the treatment may improve biomarkers of kidney function. Three of four immunoglobulin biomarkers decreased, while telomere length and mtDNA‐CN were not significantly affected by the treatment. The treatment reduced DNA methylation‐based GrimAge by an average of 0.82 years (p = 0.0093), suggests a reduction in morbidity and mortality risk. By contrast, no significant results could be observed for epigenetic clocks that estimate chronological age. Our results support the view that plasma concentrate contains youth‐promoting factors. Plasma transfusions are standard treatments to replace missing proteins in people with rare genetic diseases. Prior studies have demonstrated that heterochronic parabiosis has beneficial effects on several tissues of old animals receiving young blood. Human clinical trials are currently underway to investigate whether the infusion of plasma or plasma-derived factors from young donors can be used to mitigate human age-related conditions. Here, we use data from a safety study (n = 18, mean age 74) to investigate whether human umbilical cord plasma concentrate (hereinafter Plasma Concentrate) injected weekly (1 ml intramuscular) into elderly human subjects over a 10-week period affects different biomarkers, including epigenetic age measures, standard clinical biomarkers of organ dysfunction, mitochondrial DNA copy number (mtDNA-CN), and leukocyte telomere length. This study shows that treatment with plasma concentrate is safe. More than 20 clinical biomarkers were significantly and beneficially altered following the treatments. For example, creatinine was significantly decreased (p = 0.0039), while estimated glomerular filtration rate (eGFR) was increased (p = 0.0044), indicating the treatment may improve biomarkers of kidney function. Three of four immunoglobulin biomarkers decreased, while telomere length and mtDNA-CN were not significantly affected by the treatment. The treatment reduced DNA methylation-based GrimAge by an average of 0.82 years (p = 0.0093), suggests a reduction in morbidity and mortality risk. By contrast, no significant results could be observed for epigenetic clocks that estimate chronological age. Our results support the view that plasma concentrate contains youth-promoting factors.Plasma transfusions are standard treatments to replace missing proteins in people with rare genetic diseases. Prior studies have demonstrated that heterochronic parabiosis has beneficial effects on several tissues of old animals receiving young blood. Human clinical trials are currently underway to investigate whether the infusion of plasma or plasma-derived factors from young donors can be used to mitigate human age-related conditions. Here, we use data from a safety study (n = 18, mean age 74) to investigate whether human umbilical cord plasma concentrate (hereinafter Plasma Concentrate) injected weekly (1 ml intramuscular) into elderly human subjects over a 10-week period affects different biomarkers, including epigenetic age measures, standard clinical biomarkers of organ dysfunction, mitochondrial DNA copy number (mtDNA-CN), and leukocyte telomere length. This study shows that treatment with plasma concentrate is safe. More than 20 clinical biomarkers were significantly and beneficially altered following the treatments. For example, creatinine was significantly decreased (p = 0.0039), while estimated glomerular filtration rate (eGFR) was increased (p = 0.0044), indicating the treatment may improve biomarkers of kidney function. Three of four immunoglobulin biomarkers decreased, while telomere length and mtDNA-CN were not significantly affected by the treatment. The treatment reduced DNA methylation-based GrimAge by an average of 0.82 years (p = 0.0093), suggests a reduction in morbidity and mortality risk. By contrast, no significant results could be observed for epigenetic clocks that estimate chronological age. Our results support the view that plasma concentrate contains youth-promoting factors. |
| Author | Lu, Ake T. Brooke, Robert T. Yan, Qi Coronado, Ramon E. Agrawal, Megha Clement, James Horvath, Steve Sturges, John A. Horvath, Markus |
| AuthorAffiliation | 11 Department of Biostatistics, Fielding School of Public Health University of California Los Angeles California USA 3 Epigenetic Clock Development Foundation Torrance California USA 5 Department of Obstetrics and Gynecology Baylor College of Medicine Houston Texas USA 2 Department of Chemical, Pharmaceutical and Agricultural Sciences University of Ferrara Ferrara Italy 6 Signature Biologics Irving Texas USA 4 Transplant Department, UT Health San Antonio San Antonio Texas USA 8 John A Sturges, M.D. Coeur d'Alene Idaho USA 1 Betterhumans Inc. Gainesville Florida USA 10 Altos Labs San Diego USA 7 Crown Scientific San Antonio Texas USA 9 Department of Human Genetics, David Geffen School of Medicine University of California Los Angeles California USA |
| AuthorAffiliation_xml | – name: 5 Department of Obstetrics and Gynecology Baylor College of Medicine Houston Texas USA – name: 7 Crown Scientific San Antonio Texas USA – name: 6 Signature Biologics Irving Texas USA – name: 8 John A Sturges, M.D. Coeur d'Alene Idaho USA – name: 9 Department of Human Genetics, David Geffen School of Medicine University of California Los Angeles California USA – name: 10 Altos Labs San Diego USA – name: 4 Transplant Department, UT Health San Antonio San Antonio Texas USA – name: 1 Betterhumans Inc. Gainesville Florida USA – name: 2 Department of Chemical, Pharmaceutical and Agricultural Sciences University of Ferrara Ferrara Italy – name: 3 Epigenetic Clock Development Foundation Torrance California USA – name: 11 Department of Biostatistics, Fielding School of Public Health University of California Los Angeles California USA |
| Author_xml | – sequence: 1 givenname: James surname: Clement fullname: Clement, James email: jclement@betterhumans.org organization: University of Ferrara – sequence: 2 givenname: Qi surname: Yan fullname: Yan, Qi organization: Epigenetic Clock Development Foundation – sequence: 3 givenname: Megha surname: Agrawal fullname: Agrawal, Megha organization: Betterhumans Inc – sequence: 4 givenname: Ramon E. surname: Coronado fullname: Coronado, Ramon E. organization: Crown Scientific – sequence: 5 givenname: John A. surname: Sturges fullname: Sturges, John A. organization: John A Sturges, M.D – sequence: 6 givenname: Markus surname: Horvath fullname: Horvath, Markus organization: Epigenetic Clock Development Foundation – sequence: 7 givenname: Ake T. surname: Lu fullname: Lu, Ake T. organization: Altos Labs – sequence: 8 givenname: Robert T. surname: Brooke fullname: Brooke, Robert T. organization: Epigenetic Clock Development Foundation – sequence: 9 givenname: Steve orcidid: 0000-0002-4110-3589 surname: Horvath fullname: Horvath, Steve email: shorvath@mednet.ucla.edu organization: University of California |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36052758$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kV1rFDEUhoNU7Ife-AMk4I0UtiaZfMzcCMvaVmHRG3sdksyZbmoms01mKvvvTXfaokUMhJyQ57y8J-8xOohDBITeUnJGy_poHIQzWslGvkBHlCu-aBSTB081rQ_Rcc43hFDVkOoVOqwkEUyJ-gjdXvXWB-9MwG5ILd4Gk3tT6uggjsmMgDcmYwsROu98waDrwI0ZDxF__rbEPYybXTCjL_fL5PvlNWATW7yZehOxCz7uxa0fepN-Qsqv0cvOhAxvHs4TdHVx_mP1ZbH-fvl1tVwvHOe1XBhRW9UwwShjDFzH28a2RFJurJWtla6treSmcVUZ1si6VcIJRyoKXBBLZHWCPs2628n20M7jBL0tHk3a6cF4_fdL9Bt9PdzpRihVdhH48CCQhtsJ8qh7n8tXBxNhmLJmijSKU8mrgr5_ht4MU4plvEIxIajgjBXq3Z-Onqw8plEAMgMuDTkn6LTz4_5ri0EfNCX6PnB9H7jeB15aTp-1PKr-E6Yz_MsH2P2H1MvV-Xru-Q1XB7yV |
| CitedBy_id | crossref_primary_10_3390_ijms25126793 crossref_primary_10_1016_j_cell_2023_08_003 crossref_primary_10_1038_s41392_025_02145_7 crossref_primary_10_1007_s10522_023_10077_4 crossref_primary_10_3389_fendo_2024_1372518 crossref_primary_10_3389_fragi_2023_1112109 crossref_primary_10_1007_s11357_023_00980_6 crossref_primary_10_1038_s41598_023_50495_5 crossref_primary_10_1038_s42003_024_06609_4 crossref_primary_10_1016_j_arr_2023_101956 crossref_primary_10_1038_s43587_023_00557_0 crossref_primary_10_1016_j_heliyon_2024_e32652 |
| Cites_doi | 10.18632/aging.103418 10.1186/1471-2105-14-128 10.1161/CIRCRESAHA.108.176826 10.4252/wjsc.v6.i2.195 10.1016/j.bbrc.2015.09.166 10.1016/j.molcel.2012.10.016 10.1161/CIRCULATIONAHA.110.979740 10.7554/eLife.51507 10.1002/jca.21705 10.1016/j.bbamcr.2017.05.007 10.1016/j.mad.2019.111120 10.1186/gb-2013-14-10-r115 10.1001/jamaneurol.2016.3185 10.1016/j.yexcr.2004.12.013 10.1097/MNH.0000000000000115 10.1038/s41586-022-04722-0 10.1038/nm.3569 10.1093/bioinformatics/btu049 10.1016/j.cell.2013.05.039 10.1186/1471-2105-13-86 10.18632/aging.101684 10.3390/ijms22168889 10.1093/infdis/jiv277 10.1111/trf.14165 10.1016/j.stem.2012.02.005 10.1038/nature22067 10.1038/nature03260 10.18632/aging.101414 10.1093/eurheartj/ehl455 10.1038/s41576-018-0004-3 10.1038/nbt.1630 10.1111/acel.13028 10.3390/biom11081191 10.1155/2017/7089493 10.18632/aging.102173 10.18632/aging.103950 10.3390/ijms23010566 10.18632/aging.101508 10.1124/pr.112.005983 10.1101/gad.229102 10.1155/2016/7653489 10.1001/jamaneurol.2018.3288 10.1093/nar/gkx1042 10.1038/s41569-018-0064-2 10.1093/gerona/glaa286 |
| ContentType | Journal Article |
| Copyright | 2022 The Authors. published by Anatomical Society and John Wiley & Sons Ltd. 2022 The Authors. Aging Cell published by Anatomical Society and John Wiley & Sons Ltd. 2022. This article is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: 2022 The Authors. published by Anatomical Society and John Wiley & Sons Ltd. – notice: 2022 The Authors. Aging Cell published by Anatomical Society and John Wiley & Sons Ltd. – notice: 2022. This article is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | 24P AAYXX CITATION CGR CUY CVF ECM EIF NPM 7QP 7TK 7X8 5PM |
| DOI | 10.1111/acel.13696 |
| DatabaseName | Wiley-Blackwell Open Access Titles CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Calcium & Calcified Tissue Abstracts Neurosciences Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Calcium & Calcified Tissue Abstracts Neurosciences Abstracts MEDLINE - Academic |
| DatabaseTitleList | CrossRef MEDLINE Calcium & Calcified Tissue Abstracts MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: 24P name: Wiley Online Library Open Access url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| DocumentTitleAlternate | Clement et al |
| EISSN | 1474-9726 |
| EndPage | n/a |
| ExternalDocumentID | PMC9577957 36052758 10_1111_acel_13696 ACEL13696 |
| Genre | article Research Support, Non-U.S. Gov't Journal Article |
| GrantInformation_xml | – fundername: LongeCity – fundername: Methuselah Foundation – fundername: Betterhumans Inc – fundername: National Institute on Aging funderid: 1U01AG060908 – fundername: ; grantid: 1U01AG060908 |
| GroupedDBID | --- .3N .GA .Y3 05W 0R~ 10A 1OC 23M 24P 2WC 31~ 36B 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52W 52X 53G 5GY 5HH 5LA 5VS 66C 6J9 702 7PT 8-0 8-1 8-3 8-4 8-5 8FE 8FH 8UM 930 A01 A03 AAHHS AAZKR ABCQN ABDBF ABEML ABJNI ACCFJ ACCMX ACGFO ACGFS ACPRK ACSCC ACUHS ACXQS ADBBV ADKYN ADRAZ ADZMN ADZOD AEEZP AEGXH AENEX AEQDE AFBPY AFEBI AFKRA AFZJQ AIAGR AIWBW AJBDE ALMA_UNASSIGNED_HOLDINGS ALUQN AOIJS AVUZU BAWUL BBNVY BCNDV BENPR BFHJK BHPHI BY8 CAG CCPQU COF CS3 D-6 D-7 D-E D-F DIK DR2 E3Z EAD EAP EBD EBS EJD EMB EMK EMOBN EST ESX F00 F01 F04 F5P FIJ GODZA GROUPED_DOAJ GX1 HCIFZ HF~ HOLLA HZ~ IAO IHE IHR IPNFZ ITC IX1 J0M K.9 KQ8 LC2 LC3 LH4 LK8 LP6 LP7 LW6 M48 M7P MK4 N04 N05 N9A O9- OBS OIG OK1 OVD P2P P2X P2Z P4B P4D PIMPY Q11 ROL RPM RX1 SUPJJ SV3 TEORI TR2 TUS UB1 V8K W8V WIN WQJ WRC WXI XG1 YFH YUY ~IA ~WT AAYXX CITATION PHGZM PHGZT CGR CUY CVF ECM EIF NPM 7QP 7TK AAMMB AEFGJ AGXDD AIDQK AIDYY PQGLB 7X8 5PM |
| ID | FETCH-LOGICAL-c4486-a58b792521222ecf4d9bd0614abb6db6cd8b64a9c3972a68d75c5c031e450b063 |
| IEDL.DBID | M48 |
| ISSN | 1474-9718 1474-9726 |
| IngestDate | Thu Aug 21 18:39:45 EDT 2025 Fri Jul 11 09:18:41 EDT 2025 Wed Aug 13 08:17:37 EDT 2025 Wed Feb 19 02:26:29 EST 2025 Tue Jul 01 01:49:18 EDT 2025 Thu Apr 24 23:10:54 EDT 2025 Wed Jan 22 16:22:32 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 10 |
| Keywords | clinical trial epigenetic clocks young plasma umbilical cord plasma exosome treatment |
| Language | English |
| License | Attribution 2022 The Authors. Aging Cell published by Anatomical Society and John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4486-a58b792521222ecf4d9bd0614abb6db6cd8b64a9c3972a68d75c5c031e450b063 |
| Notes | James Clement and Qi Yan Joint First Author. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0002-4110-3589 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1111/acel.13696 |
| PMID | 36052758 |
| PQID | 2725515422 |
| PQPubID | 1036381 |
| PageCount | 15 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_9577957 proquest_miscellaneous_2709741643 proquest_journals_2725515422 pubmed_primary_36052758 crossref_citationtrail_10_1111_acel_13696 crossref_primary_10_1111_acel_13696 wiley_primary_10_1111_acel_13696_ACEL13696 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | October 2022 |
| PublicationDateYYYYMMDD | 2022-10-01 |
| PublicationDate_xml | – month: 10 year: 2022 text: October 2022 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London – name: Hoboken |
| PublicationTitle | Aging cell |
| PublicationTitleAlternate | Aging Cell |
| PublicationYear | 2022 |
| Publisher | John Wiley & Sons, Inc John Wiley and Sons Inc |
| Publisher_xml | – name: John Wiley & Sons, Inc – name: John Wiley and Sons Inc |
| References | 2002; 16 2013; 49 2021; 22 2017; 2017 2015; 467 2019; 11 2017; 1864 2019; 76 2005; 433 2019; 34 2022; 23 2019; 18 2016; 73 2016; 2016 2020; 12 2008; 103 2020; 76 2012; 13 2012; 10 2018; 46 2014; 20 2015; 24 2007; 28 2018; 19 2013; 14 2019; 181 2021; 11 2015; 212 2010; 28 2017; 57 2020; 9 2005; 305 2022; 605 2013; 153 2014; 30 2018; 10 2014; 6 2017; 544 2011; 123 2018; 15 2012; 64 e_1_2_9_30_1 e_1_2_9_31_1 e_1_2_9_11_1 e_1_2_9_34_1 e_1_2_9_10_1 e_1_2_9_35_1 e_1_2_9_13_1 e_1_2_9_32_1 e_1_2_9_12_1 e_1_2_9_33_1 e_1_2_9_38_1 e_1_2_9_14_1 e_1_2_9_39_1 e_1_2_9_17_1 e_1_2_9_36_1 e_1_2_9_16_1 e_1_2_9_37_1 e_1_2_9_19_1 e_1_2_9_18_1 e_1_2_9_41_1 Han C. (e_1_2_9_15_1) 2016; 2016 e_1_2_9_42_1 e_1_2_9_20_1 e_1_2_9_40_1 e_1_2_9_22_1 e_1_2_9_45_1 e_1_2_9_21_1 e_1_2_9_46_1 e_1_2_9_24_1 e_1_2_9_43_1 e_1_2_9_23_1 e_1_2_9_44_1 e_1_2_9_8_1 e_1_2_9_7_1 e_1_2_9_6_1 e_1_2_9_5_1 e_1_2_9_4_1 e_1_2_9_3_1 e_1_2_9_2_1 e_1_2_9_9_1 e_1_2_9_26_1 e_1_2_9_25_1 e_1_2_9_28_1 e_1_2_9_27_1 e_1_2_9_29_1 |
| References_xml | – volume: 181 start-page: 47 year: 2019 end-page: 58 article-title: Attenuation of frailty in older adults with mesenchymal stem cells publication-title: Mechanisms of Ageing and Development – volume: 28 start-page: 478 year: 2007 end-page: 483 article-title: The glomerular filtration rate in an apparently healthy population and its relation with cardiovascular mortality during 10 years publication-title: European Heart Journal – volume: 12 start-page: 12 year: 2020 end-page: 17894 article-title: Epigenetic mutation load is weakly correlated with epigenetic age acceleration publication-title: Aging – volume: 153 start-page: 1194 year: 2013 end-page: 1217 article-title: The hallmarks of aging publication-title: Cell – volume: 13 start-page: 86 year: 2012 article-title: DNA methylation arrays as surrogate measures of cell mixture distribution publication-title: BMC Bioinformatics – volume: 76 start-page: 741 year: 2020 end-page: 749 article-title: GrimAge outperforms other epigenetic clocks in the prediction of age‐related clinical phenotypes and all‐cause mortality publication-title: The Journals of Gerontology: Series A – volume: 467 start-page: 303 year: 2015 end-page: 309 article-title: Human fibrocyte‐derived exosomes accelerate wound healing in genetically diabetic mice publication-title: Biochemical and Biophysical Research Communications – volume: 6 start-page: 195 year: 2014 end-page: 202 article-title: Umbilical cord‐derived mesenchymal stem cells: Their advantages and potential clinical utility publication-title: World Journal of Stem Cells – volume: 2016 start-page: 1 year: 2016 end-page: 11 article-title: Exosomes and their therapeutic potentials of stem cells publication-title: Stem Cells International – volume: 10 start-page: 573 year: 2018 end-page: 591 article-title: An epigenetic biomarker of aging for lifespan and healthspan publication-title: Aging (Albany NY) – volume: 28 start-page: 495 year: 2010 end-page: 501 article-title: GREAT improves functional interpretation of cis‐regulatory regions publication-title: Nature Biotechnology – volume: 34 start-page: 171 year: 2019 end-page: 354 article-title: Guidelines on the use of therapeutic apheresis in clinical practice – Evidence‐based approach from the writing Committee of the American Society for apheresis: The eighth special issue publication-title: Journal of Clinical Apheresis – volume: 10 start-page: 244 year: 2012 end-page: 258 article-title: Harnessing the mesenchymal stem cell secretome for the treatment of cardiovascular disease publication-title: Cell Stem Cell – volume: 57 start-page: 1588 year: 2017 end-page: 1598 article-title: Continued decline in blood collection and transfusion in the United States–2015 publication-title: Transfusion – volume: 305 start-page: 33 year: 2005 end-page: 41 article-title: Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms publication-title: Experimental Cell Research – volume: 73 start-page: 1325 year: 2016 end-page: 1333 article-title: Preclinical assessment of young blood plasma for Alzheimer disease publication-title: JAMA Neurology – volume: 103 start-page: 1204 year: 2008 end-page: 1219 article-title: Paracrine mechanisms in adult stem cell signaling and therapy publication-title: Circulation Research – volume: 20 start-page: 659 year: 2014 end-page: 663 article-title: Young blood reverses age‐related impairments in cognitive function and synaptic plasticity in mice publication-title: Nature Medicine – volume: 23 start-page: 566 year: 2022 article-title: Metabolic rewiring by human placenta‐derived mesenchymal stem cell therapy promotes rejuvenation in aged female rats publication-title: International Journal of Molecular Sciences – volume: 64 start-page: 676 year: 2012 end-page: 705 article-title: Classification, functions, and clinical relevance of extracellular vesicles publication-title: Pharmacological Reviews – volume: 76 start-page: 35 year: 2019 end-page: 40 article-title: Safety, tolerability, and feasibility of young plasma infusion in the plasma for Alzheimer symptom amelioration study publication-title: JAMA Neurology – volume: 15 start-page: 505 year: 2018 end-page: 522 article-title: Inflammageing: Chronic inflammation in ageing, cardiovascular disease, and frailty publication-title: Nature Reviews. Cardiology – volume: 30 start-page: 1363 year: 2014 end-page: 1369 article-title: Minfi: A flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays publication-title: Bioinformatics – volume: 605 start-page: 509 year: 2022 end-page: 515 article-title: Young CSF restores oligodendrogenesis and memory in aged mice via Fgf17 publication-title: Nature – volume: 1864 start-page: 2015 year: 2017 end-page: 2025 article-title: The role of matrix metalloproteinases in aging: Tissue remodeling and beyond publication-title: Biochimica et Biophysica Acta, Molecular Cell Research – volume: 16 start-page: 2264 year: 2002 end-page: 2273 article-title: Disruption of the gene encoding the latent transforming growth factor‐β binding protein 4 (LTBP‐4) causes abnormal lung development, cardiomyopathy, and colorectal cancer publication-title: Genes & Development – volume: 11 start-page: 11 year: 2021 article-title: Young and undamaged rMSA improves the Healthspan and lifespan of mice publication-title: Biomolecules – volume: 19 start-page: 371 year: 2018 end-page: 384 article-title: DNA methylation‐based biomarkers and the epigenetic clock theory of ageing publication-title: Nature Reviews. Genetics – volume: 24 start-page: 295 year: 2015 end-page: 300 article-title: Cystatin C as a biomarker for estimating glomerular filtration rate publication-title: Current Opinion in Nephrology and Hypertension – volume: 10 start-page: 1758 year: 2018 end-page: 1775 article-title: Epigenetic clock for skin and blood cells applied to Hutchinson Gilford progeria syndrome and ex vivo studies publication-title: Aging (Albany NY) – volume: 2017 start-page: 7089493 year: 2017 article-title: Red blood cell distribution width: A novel predictive indicator for cardiovascular and cerebrovascular diseases publication-title: Disease Markers – volume: 22 start-page: 8889 year: 2021 article-title: GDF15 and cardiac cells: Current concepts and new insights publication-title: International Journal of Molecular Sciences – volume: 11 start-page: 303 year: 2019 end-page: 327 article-title: DNA methylation GrimAge strongly predicts lifespan and healthspan publication-title: Aging (Albany NY) – volume: 123 start-page: 2101 year: 2011 end-page: 2110 article-title: Growth‐differentiation Factor‐15 is a robust, independent predictor of 11‐year mortality risk in community‐dwelling older adults publication-title: Circulation – volume: 11 start-page: 5895 year: 2019 end-page: 5923 article-title: DNA methylation‐based estimator of telomere length publication-title: Aging (Albany NY) – volume: 46 start-page: D1083 year: 2018 end-page: D1090 article-title: Human ageing genomic resources: New and updated databases publication-title: Nucleic Acids Research – volume: 14 start-page: 128 year: 2013 article-title: Enrichr: Interactive and collaborative HTML5 gene list enrichment analysis tool publication-title: BMC Bioinformatics – volume: 18 issue: 6 year: 2019 article-title: Reversal of epigenetic aging and immunosenescent trends in humans publication-title: Aging Cell – volume: 14 start-page: R115 year: 2013 article-title: DNA methylation age of human tissues and cell types publication-title: Genome Biology – volume: 49 start-page: 359 year: 2013 end-page: 367 article-title: Genome‐wide methylation profiles reveal quantitative views of human aging rates publication-title: Molecular Cell – volume: 12 start-page: 8790 year: 2020 end-page: 8819 article-title: Rejuvenation of three germ layers tissues by exchanging old blood plasma with saline‐albumin publication-title: Aging – volume: 9 year: 2020 article-title: Longitudinal trajectories, correlations and mortality associations of nine biological ages across 20‐years follow‐up publication-title: eLife – volume: 433 start-page: 760 year: 2005 end-page: 764 article-title: Rejuvenation of aged progenitor cells by exposure to a young systemic environment publication-title: Nature – volume: 212 start-page: 1563 year: 2015 end-page: 1573 article-title: HIV‐1 infection accelerates age according to the epigenetic clock publication-title: The Journal of Infectious Diseases – volume: 544 start-page: 488 year: 2017 end-page: 492 article-title: Human umbilical cord plasma proteins revitalize hippocampal function in aged mice publication-title: Nature – ident: e_1_2_9_32_1 doi: 10.18632/aging.103418 – ident: e_1_2_9_4_1 doi: 10.1186/1471-2105-14-128 – ident: e_1_2_9_14_1 doi: 10.1161/CIRCRESAHA.108.176826 – ident: e_1_2_9_34_1 doi: 10.4252/wjsc.v6.i2.195 – ident: e_1_2_9_13_1 doi: 10.1016/j.bbrc.2015.09.166 – ident: e_1_2_9_16_1 doi: 10.1016/j.molcel.2012.10.016 – ident: e_1_2_9_6_1 doi: 10.1161/CIRCULATIONAHA.110.979740 – ident: e_1_2_9_26_1 doi: 10.7554/eLife.51507 – ident: e_1_2_9_35_1 doi: 10.1002/jca.21705 – ident: e_1_2_9_12_1 doi: 10.1016/j.bbamcr.2017.05.007 – ident: e_1_2_9_11_1 doi: 10.1016/j.mad.2019.111120 – ident: e_1_2_9_17_1 doi: 10.1186/gb-2013-14-10-r115 – ident: e_1_2_9_33_1 doi: 10.1001/jamaneurol.2016.3185 – ident: e_1_2_9_38_1 doi: 10.1016/j.yexcr.2004.12.013 – ident: e_1_2_9_9_1 doi: 10.1097/MNH.0000000000000115 – ident: e_1_2_9_22_1 doi: 10.1038/s41586-022-04722-0 – ident: e_1_2_9_45_1 doi: 10.1038/nm.3569 – ident: e_1_2_9_2_1 doi: 10.1093/bioinformatics/btu049 – ident: e_1_2_9_27_1 doi: 10.1016/j.cell.2013.05.039 – ident: e_1_2_9_21_1 doi: 10.1186/1471-2105-13-86 – ident: e_1_2_9_28_1 doi: 10.18632/aging.101684 – ident: e_1_2_9_39_1 doi: 10.3390/ijms22168889 – ident: e_1_2_9_18_1 doi: 10.1093/infdis/jiv277 – ident: e_1_2_9_7_1 doi: 10.1111/trf.14165 – ident: e_1_2_9_37_1 doi: 10.1016/j.stem.2012.02.005 – ident: e_1_2_9_3_1 doi: 10.1038/nature22067 – ident: e_1_2_9_5_1 doi: 10.1038/nature03260 – ident: e_1_2_9_24_1 doi: 10.18632/aging.101414 – ident: e_1_2_9_44_1 doi: 10.1093/eurheartj/ehl455 – ident: e_1_2_9_20_1 doi: 10.1038/s41576-018-0004-3 – ident: e_1_2_9_31_1 doi: 10.1038/nbt.1630 – ident: e_1_2_9_8_1 doi: 10.1111/acel.13028 – ident: e_1_2_9_43_1 doi: 10.3390/biom11081191 – ident: e_1_2_9_25_1 doi: 10.1155/2017/7089493 – ident: e_1_2_9_29_1 doi: 10.18632/aging.102173 – ident: e_1_2_9_46_1 doi: 10.18632/aging.103950 – ident: e_1_2_9_23_1 doi: 10.3390/ijms23010566 – ident: e_1_2_9_19_1 doi: 10.18632/aging.101508 – ident: e_1_2_9_36_1 doi: 10.1124/pr.112.005983 – ident: e_1_2_9_41_1 doi: 10.1101/gad.229102 – volume: 2016 start-page: 1 year: 2016 ident: e_1_2_9_15_1 article-title: Exosomes and their therapeutic potentials of stem cells publication-title: Stem Cells International doi: 10.1155/2016/7653489 – ident: e_1_2_9_40_1 doi: 10.1001/jamaneurol.2018.3288 – ident: e_1_2_9_42_1 doi: 10.1093/nar/gkx1042 – ident: e_1_2_9_10_1 doi: 10.1038/s41569-018-0064-2 – ident: e_1_2_9_30_1 doi: 10.1093/gerona/glaa286 |
| SSID | ssj0017903 |
| Score | 2.4873545 |
| Snippet | Plasma transfusions are standard treatments to replace missing proteins in people with rare genetic diseases. Prior studies have demonstrated that... |
| SourceID | pubmedcentral proquest pubmed crossref wiley |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | e13696 |
| SubjectTerms | Adolescent Age Aged Aging - genetics Biomarkers Biomarkers - metabolism clinical trial Clinical trials Copy number Creatinine DNA methylation DNA Methylation - genetics DNA, Mitochondrial - genetics DNA, Mitochondrial - metabolism Epigenesis, Genetic epigenetic clocks Epigenetics exosome treatment Genetic disorders Glomerular filtration rate Humans Infant Mitochondrial DNA Morbidity Parabiosis Plasma Telomeres Umbilical cord Umbilical Cord - metabolism umbilical cord plasma young plasma |
| SummonAdditionalLinks | – databaseName: Wiley Online Library - Core collection (SURFmarket) dbid: DR2 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9tAEB5CoNBLn2mrNC1bmksLCvZ6pdVCLybNg9LmEGLIpYjZ1ToJieXUj0P66zuzK6lxUwLtwSDQGK9WM6Nv5G--AdgmP_B63O-nOq8GqUK0KQ6QipU-Kqmdc5Xn5uRvR_nhSH05zU7X4FPbCxP1IboXbhwZIV9zgKOd3wpydP6KSVqG9baZrMWI6LjTjmLlqcCuV1qlhjJwo03KNJ7fX119Gt2BmHeZkrcRbHgE7T-G7-3iI_Pkcme5sDvu5x-6jv97dU_gUYNNxTA601NY8_UzeBCnVd48hx-jCTNp6aYKLlnFNQHvCdJxHde98OIc58JS9oyyFKIhi4hpLT4fDQVPq76J3DtxMLuYDM-8wLoSYU6gaHs0BSsCMGloNt-A0f7eye5h2kxsSB2VeXmKWWG1kdwPLKV3Y1UZW3HNidbmlc1dVdhcoXGEgiTmRaUzlznKK15lPUto6QWs19PavwJBuKFA6yghj3PuvDZF1hsXPZRaE4pSJoEP7Z0rXSNnzlM1rsq2rOEtLMMWJvC-s72OIh5_tdpqHaBsAnleSk01F8FMKRN4152mEOT_VbD20yXb9AwDWzVI4GX0l-5nBlQuSqrJEtArntQZsLz36pn64jzIfJtMa_ok8DE4yj0rL4e7e1_D0ea_GL-Gh5KbOQI1cQvWF7Olf0MQa2HfhlD6BQ2oIzo priority: 102 providerName: Wiley-Blackwell |
| Title | Umbilical cord plasma concentrate has beneficial effects on DNA methylation GrimAge and human clinical biomarkers |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Facel.13696 https://www.ncbi.nlm.nih.gov/pubmed/36052758 https://www.proquest.com/docview/2725515422 https://www.proquest.com/docview/2709741643 https://pubmed.ncbi.nlm.nih.gov/PMC9577957 |
| Volume | 21 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1bT9swFD7iokl7mRjskg0qT-OFSZla17HjB4Q6VoYmqBBaJd4i23EBqU2hLRL995zjJIUKNPGQyJKdm4_t833xuQDs4jjwatBqxUrm7VgYY2PTNkhWWkZw5ZzLPTknn_bkcV_8vUguVqDO31l14PRFakf5pPqT4c_72_kBTvj92irHOD8kcy0tV2EdNZKiCXoqHncTlA4ZkltCiVjjYlyFKV2-dlkxPUObz40mn4LZoI2ONuBdBSNZp5T7e1jxxSa8KRNLzrfgtj8io1fsf0bskt0gRh4ZLBflfWeeXZkps7jQlREkWGXXwcYF-93rMEosPS_N5NifyfWoc-mZKXIWUvqx2p2SkfM-2fdMph-gf9T9d3gcV8kVYoeMTMYmSa3SnFx3OfduIHJtc6KHxlqZW-ny1EphtEPAwo1Mc5W4xOES4EXStAhsPsJaMS78Z2Co4lNjHa6dA0lO0jpNmoO0abhSCHiEjmCv7tnMVZHHKQHGMKsZCEkhC1KI4Pui7U0Zb-PFVtu1gLJ6yGRcIT1CRMh5BN8W1ThbaAvEFH58R22amjCoaEfwqZTn4jFtZHYc6VMEaknSiwYUiXu5pri-ChG5daIUHhH8CGPiP2-edQ67J6H05VVf-hXecnK4COaD27A2m9z5HYRBM9uAVS7OGrD-q9s7O2-Enwl0PueNMPofAMqWCpA |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEB71IVQuvAuGAovgApKjZLPe9R6j0hIgzQE1Um_W7nrTVm2ckseh_Hpmdh3TUIQEB0uWPJZfM-Nv7G--AXiHfuDVuNNJlSy7qTDGpqZrsFjpGMGVc6701Jx8NJT9kfhykp3U3BzqhYn6EM0HN4qMkK8pwOmD9I0oN85fEktLy03YppHeoaL61qhHkfZU4NcLJVKNObhWJyUiz699199Ht0Dmba7kTQwbXkKH9-Ok1XnQLiTuyUVrubAt9-M3Zcf_vr4HcK-Gp6wX_ekhbPjqEdyJAyuvH8P30YTItPhcGVWt7Aqx98TgehVPfOHZmZkziwk0KlOwmi_CphX7OOwxGlh9Hel37NPsfNI79cxUJQujAtmqTZORKADxhmbzJzA6PDje76f10IbUYaUnU5PlVmlOLcGcezcWpbYllZ3GWlla6crcSmG0QyDEjcxLlbnMYWrxImtbBEy7sFVNK_8MGEKH3FiHOXksqfla51l7nLcNVwqBlNAJvF89usLViuY0WOOyWFU2dAuLcAsTeNvYXkUdjz9a7a08oKhjeV5whWUXIk3OE3jTbMYopF8rpvLTJdm0NWFb0U3gaXSY5jBdrBg5lmUJqDVXagxI4Xt9S3V-FpS-daYULgl8CJ7ylzMvevsHg7D2_F-MX8NO__hoUAw-D7--gLucejsCU3EPthazpX-JiGthX4W4-gkhWSdV |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1JaxRBFH7EBMWLuNtZtEQvCg0zNdVdXZBLk2SMGgcPtgQvTW1tApmeyczkkH_ve9WLGRIEDw0F9Xqh3lLf63oLwHuUAy-r4TCWqRvFQmsT65FGZ2WoBZfWWucpOfnbJD0uxJfT5HQD9rtcmKY-RP_DjTQj2GtS8Lmrbii5tv6CgrRUeg-2qEweyvRW_rP4VfSnCFKFzshDIUWs0Ai35Ukpkufv3esb0i2UeTtY8iaIDbvQ-DE8auEjyxt-P4ENXz-F-01DyetncFlMKdgV152RV8nmiI2nGsd189yVZ2d6yQwauKZyBGvjOdisZoeTnFFD6esmPI59WpxP89-e6dqx0MqPdWmUjJL2Ka5nsXwOxfjox8Fx3DZViC16Ymmsk8xIxSlll3NvK-GUceQWamNSZ1LrMpMKrSwCFa7TzMnEJhZV34tkYBDQvIDNelb7V8Bwa8-0sWgzq5SSo1WWDKpsoLmUCHSEiuBDt7KlbSuOU-OLi7LzPIgLZeBCBO962nlTZ-NOqt2OQWWra8uSS3SLEAlyHsHbfhq1hI4-dO1nV0QzUIQ9xSiClw0_-9eM0KPj6DZFINc43RNQBe71mfr8LFTiVomUeEXwMcjEP768zA-OTsJo-3-I38CD74fj8uTz5OsOPOSUehECCXdhc7W48nsIiFbmdSv3fwDh8gc5 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Umbilical+cord+plasma+concentrate+has+beneficial+effects+on+DNA+methylation+GrimAge+and+human+clinical+biomarkers&rft.jtitle=Aging+cell&rft.au=Clement%2C+James&rft.au=Yan%2C+Qi&rft.au=Agrawal%2C+Megha&rft.au=Coronado%2C+Ramon+E.&rft.date=2022-10-01&rft.issn=1474-9718&rft.eissn=1474-9726&rft.volume=21&rft.issue=10&rft_id=info:doi/10.1111%2Facel.13696&rft.externalDBID=n%2Fa&rft.externalDocID=10_1111_acel_13696 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1474-9718&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1474-9718&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1474-9718&client=summon |